Platelet-derived 12-hydroxyeicosatetraenoic acid plays an important role in mediating canine coronary thrombosis by regulating platelet glycoprotein IIb/IIIa activation

Circulation

Volumn 98, Issue 25, 1998, Pages 2891-2898

  Katoh, Atsushi ^b   Ikeda, Hisao ^a   Murohara, Toyoaki ^b   Haramaki, Nobuya ^b   Ito, Hideki ^b   Imaizumi, Tsutomu ^b  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

Glycoproteins; Hydroxyeicosatetraenoic acid; Platelet aggregation; Platelets; Thrombosis

Indexed keywords

12 HYDROXYICOSATETRAENOIC ACID; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 6 [3 (1 O TOLYLIMIDAZOL 2 YL)SYLFINYLPROPOXY] 3,4 DIHYDRO 2 (1H) QUINOLINONE; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; FIBRINOGEN RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOG; ICOSANOID METABOLISM; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

EID: 0032578975     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.25.2891     Document Type: Article

References (33)

1. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med. 1981;304:685-691.
2. Fuster V, Lewis A. Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation. 1994;90:2126-2146.
3. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation. 1989;80:198-205.
4. Mizuno K, Satomura K, Miyamoto A, Arakawa K, Shibuya T, Arai T, Kurita A, Nakamura H, Ambrose JA. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med. 1992; 326:287-291.
5. Ikeda H, Koga Y, Kuwano K, Nakayama H, Ueno T, Yoshida N, Adachi K, Park IS, Toshima H. Cyclic flow variations in a conscious dog model of coronary artery stenosis and endothelial injury correlate with acute ischemic heart disease syndromes in humans. J Am Coll Cardiol. 1993; 21:1008-1017.
6. Needleman P, Turk J, Jakschik B, Morrison A, Lefkowith J. Arachidonic acid metabolism. Annu Rev Biochem. 1986;55:69-102.
7. Kroll MH, Schafer AI. Biochemical mechanisms of platelet activation. Blood. 1989;74:1181-1195.
8. Hamberg M, Samuelsson B. Prostaglandin endoperoxides: novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci USA. 1974;71:3400-3404.
9. Folts JD, Edward B, Crowell J, Rowe GG. Platelet aggregation in partially obstructed vessels and its elimination with aspirin. Circulation. 1976;54:365-370.
10. Bush LR, Campbell WB, Buja LM, Tilton GD, Willerson JT. Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation. 1984; 69:1161-1170.
11. Fuster V, Dyken ML, Vokonas PS, Hennekens C. Aspirin as a therapeutic agent in cardiovascular disease. Circulation. 1993;87:659-675.
12. Sekiya F, Takagi J, Usui T, Kawajiri K, Kobayashi Y, Sato F, Saito Y. 12S-hydroxyeicosatetraenoic acid plays a central role in the regulation of platelet activation. Biochem Biophys Res Commun. 1991;179:345-351.
13. Ikeda H, Koga Y, Oda T, Kuwano K, Nakayama H, Ueno T, Toshima H, Michael LH, Entman ML. Free oxygen radicals contribute to platelet aggregation and cyclic flow variations in stenosed and endothelium-injured canine coronary arteries. J Am Coll Cardiol. 1994;24:1749-1756.
14. Kuwano K, Ikeda H, Oda T, Nakayama H, Koga Y, Toshima H, Imaizumi T. Xanthine oxidase mediates cyclic flow variations in a canine model of coronary arterial thrombosis. Am J Physiol. 1996;270:H1993-H1999.
15. Ueyama T, Ikeda H, Haramaki N, Kuwano K, Imaizuni T. Effects of monoclonal antibody to P-selectin and analog of sialyl lewis X on cyclic flow variations in stenosed and endothelium-injured canine arteries. Circulation. 1997;96:1554-1559.
16. Uno T, Ozeki Y, Koga Y, Chu G-N, Okada M, Tamura K, Igawa T, Unemi F, Kido M, Nishi T. Synthesis of (1H)-quinolinone derivatives and their inhibitory activity on the release of 12(S)-hydroxyeicosatetraenoic acid (12-HETE) from platelets. Chem Pharm Bull. 1995;43:1724-1733.
17. 2 receptor activation of cyclic flow variations in dogs with severe coronary artery stenoses. Circulation. 1987;76:952-959.
18. Raghunath M, Stiegeler A, Lange B, Frosch P. Extraction of various arachidonic acid metabolites from minimal amounts of biological fluid with a new generation of miniaturized solid phase extraction cartridges. J Liquid Chromatogr. 1990;13:968-980.
19. 2 antagonism prevents cyclic flow variations in stenosed and endothelium-injured arteries in nonhuman primates. Circulation. 1993;88:2888-2893.
20. Radomski M, Moncada S. An improved method for washing of human platelets with prostacyclin. Thromb Res. 1983;30:383-389.
21. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation. J Biol Chem. 1985;260:11107-11114.
22. Folts J, Gallagher K, Rowe G. Blood flow reductions in stenosed canine coronary arteries: vasospasm or platelet aggregation? Circulation. 1982; 65:248-255.
23. Bush LR, Shebuski RJ. In vivo models of arterial thrombosis and thrombolysis. FASEB J. 1990;4:3087-3098.
24. Rosolowsky M, Falack JR, Willerson JT, Campbell WB. Synthesis of lipoxygenase and epoxygenase producis of arachidonic acid by normal and stenosed canine coronary arteries. Circ Res. 1990;66:608-621.
25. Nyby MD, Sasaki M, Ideguchi Y, Wynne HE, Hori MT, Berger ME, Golub MS, Brickman AS, Tuck ML. Platelet lipoxygenase inhibitors attenuate thrombin- and thromboxane mimetic-induced intracellular calcium mobilization and platelet aggregation. J Pharmacol Exp Ther. 1996;278:503-509.
26. Nishi T, Tabusa F, Tanaka T, Shimizu T, Kanbe T, Kimura Y, Nakagawa K. Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors, II: 6-[3-(1-cyclohexyl-5-tetrazolyl)propoxy]-1,2-dihydro-2-oxoquinoline and related compounds. Chem Pharm Bull. 1985;31: 1151-1157.
27. Aharony D, Smith J, Silver M. Regulation of arachidonate-induced platelet aggregation by lipoxygenase product, 12-hydroperoxyeicosatetraenoic acid. Biochim Biophys Acta. 1982;718:193-200.
28. Coller BS. Platelets and thrombolytic therapy. N Engl J Med. 1990;322: 33-42.
29. Willerson JT. Inhibitors of platelet glycoprotein IIb/IIIa receptors: will they be useful when given chronically? Circulation. 1996;94:866-868.
30. Ozeki Y, Ito H, Nagamura Y, Unemi F, Igawa T. 12(S)-HETE plays a role as a mediator of expression of platelet CD62 (P-selectin). Platelets. 1998;9:297-302.
31. Palabrica T, Lobb R, Furie B, Aronovitz M, Benjamin C, Hsu Y, Sajer S, Furie B. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets. Nature. 1992;359:848-851.
32. Fujise K, Revelle BM, Stacy L, Madison EL, Yeh ETH, Willerson JT. A tissue plasminogen activator/P-selectin fusion protein is an effective thrombolytic agent. Circulation. 1997;95:715-722.
33. Geng JG, Bevilacqua MP, Moore KL, McIntyre TM, Prescott SM, Kim JM, Bliss GA, Zimmerman GA, McEver RP. Rapid neutrophil adhesion to activated endothelium mediated by GMP-140. Nature. 1990;343:757-760.